Our findings offer a better understanding of the role of CAMK2N1 DNA methylation in PCa and reveal a promising new approach through which CAMK2N1 and epigenetic pathways could serve as a potential predictive biomarker as well as a molecular determinant in the effective treatment of PCa. The gene discussed is CAMK2N1; the disease is posterior cortical atrophy.